newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

  • AEON Biopharma granted 150,000 restricted stock units to a newly hired non-executive employee on October 5, 2026.
  • The award was approved by the Compensation Committee under the 2025 Employment Inducement Incentive Award Plan to induce new employment.
  • The RSUs vest in four equal 25% installments on the annual anniversary of March 9, 2026.
  • The grant complies with Section 711 of the NYSE American LLC Company Guide as a material inducement.
  • AEON is advancing ABP-450 as a biosimilar to BOTOX for full-label U.S. therapeutic market entry.
  • ABP-450 is the same botulinum toxin complex marketed by Evolus for cosmetic use under the name Jeuveau.
  • The product is manufactured by Daewoong Pharmaceutical in a facility authorized by the FDA, Health Canada, 1 the EMA.
  • AEON holds exclusive development 1 distribution rights for ABP-450 therapeutic indications in the U.S., Canada, the EU, the UK, 1 other territories.
  • The U.S. therapeutic neurotoxin market exceeds $3.0 billion annually.